VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
OSCR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
OSCROscar Health, Inc.
$29.84$7.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. OSCR
  4. Financial Ratios

Oscar Health, Inc. (OSCR) Financial Ratios

Latest Ratios: P/E Ratio 12.1x · EV/EBITDA 5.6x · ROE -44.4%. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

OSCR Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$7.7B$3.8B$3.6B$2.0B$523M$1.4B——
Enterprise Value$5.4B$1.4B$2.3B$457M$-737908447$301M——
P/E Ratio →12.08—140.44—————
P/S Ratio0.440.320.390.350.130.73——
P/B Ratio7.983.843.522.520.591.01——
P/FCF1.893.563.76—1.49———
P/OCF7.073.443.65—1.37———

P/E links to full P/E history page with 30-year chart

OSCR EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue—0.120.260.08-0.180.16——
EV / EBITDA5.62—26.23—————
EV / EBIT——41.03—————
EV / FCF—1.352.47—-2.10———

OSCR Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin14.4%14.4%20.1%20.8%100.0%100.0%100.0%100.0%
Operating Margin-3.4%-3.4%0.6%-4.0%-14.8%-29.7%-68.8%-46.8%
Net Profit Margin-3.8%-3.8%0.3%-4.6%-14.7%-29.8%-69.0%-47.2%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE-44.4%-44.4%2.8%-31.9%-53.1%-1185.2%——
ROA-7.9%-7.9%0.6%-6.7%-15.4%-20.5%-22.5%-19.4%
ROIC—————-148.3%——
ROCE-25.3%-25.3%2.1%-8.8%-37.4%-48.4%-22.4%—

OSCR Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity0.440.440.290.370.33———
Debt / EBITDA——3.35—————
Net Debt / Equity—-2.39-1.21-1.95-1.41-0.79——
Net Debt / EBITDA——-13.73—————
Debt / FCF—-2.21-1.29—-3.59—-3.28—
Interest Coverage-23.85-23.852.41-9.86-25.97-119.89-114.48—

Net cash position: cash ($2.8B) exceeds total debt ($430M)

OSCR Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio0.950.950.90—1.401.71——
Quick Ratio0.950.950.90—1.401.71——
Cash Ratio0.820.820.68—1.001.05——
Asset Turnover—1.851.901.630.910.580.260.41
Inventory Turnover————————
Days Sales Outstanding————————

OSCR Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield————————
Payout Ratio————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield8.3%—0.7%—————
FCF Yield53.0%28.1%26.6%—67.2%———
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%——
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%——
Shares Outstanding—$262M$266M$222M$212M$179M$239M$239M

Key Metrics

Growth RegimeExpanding
ProfitabilityModerate
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Volatile quarterly combined ratio

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiple Outruns Trailing Returns

Based on reported figures, OSCR trades at 8.55x book value and 12.93x trailing earnings, a premium that implies returns well above the current -44.4% ROE the market has yet to see confirmed in underwriting results.

A price-to-book of 8.55 is high for a managed care carrier, and far above insurance peers such as Arch Capital at 1.70, implying the market is valuing OSCR more like a technology platform than an insurer. The trailing P/E of 12.93 looks reasonable only because recent quarterly earnings were lifted by a strong first-quarter result, so the multiple may be flattered by timing rather than durable underwriting strength. Investors should monitor whether ROE can move from the 51.3% quarterly spike toward a repeatable level, since the current premium depends on that conversion.

Combined Ratio Swings Expose Reserve Sensitivity

As reported in financial statements, OSCR's combined ratio fell from 111.9% in 2025Q4 to 84.8% in 2026Q1 before rising to 96.5% in 2026Q3, moving the book in and out of underwriting profit within two quarters.

The combined ratio has crossed the 100% threshold repeatedly, with the loss ratio ranging from 69.5% to 93.4% across the period, which suggests medical cost estimates and risk adjustment true-ups are driving large quarterly swings. A 96.5% combined ratio in the latest quarter indicates thin underwriting margin rather than a structural cushion. The pattern warrants further investigation into whether the 2026Q1 underwriting profit reflects durable pricing or favorable reserve timing.

Float Income Cannot Offset Underwriting Losses

Based on EDBL's reported figures, OSCR's ROE swung from -35.1% in 2025Q4 to 51.3% in 2026Q1 and back to 7.8% in 2026Q3, with an underwriting margin of 3.5% in the latest quarter providing only modest support.

Because the underwriting margin is only 3.5% in 2026Q3, investment income on float is a larger share of the return than it would be for a steadier underwriter, yet the investment portfolio is not separately disclosed in the supplied data and cannot be quantified. The large ROE swing relative to the modest underwriting margin suggests that a meaningful part of recent profitability may come from non-recurring items. Investors should monitor whether ROE stabilizes once reserve timing effects normalize.

Low Debt Load Masks Thin Equity Cushion

Based on reported figures, OSCR's debt-to-equity ratio of 0.19 in 2026Q3 is conservative, yet equity of $2.2B against $7.8B of liabilities leaves a capital base that rebuilt only after multiple quarters of losses.

A low debt-to-equity ratio reflects limited financial leverage, but for an insurer the more relevant measure is premium-to-surplus, which the supplied data does not report. Statutory risk-based capital ratios are data unavailable and cannot be verified here, so the capacity to absorb a loss-ratio shock cannot be confirmed. The recovery in equity from about $1.0B to $2.2B appears to depend on a few strong quarters, warranting caution about how durable the capital base is.

Premium Valuation Versus Tech-Adjacent Peers

Based on reported peer data, OSCR's 8.55x P/B sits near Alignment Healthcare's 8.28x and far above Arch Capital's 1.70x, while OSCR's 2026Q3 ROE of 7.8% lags the 18.3% achieved by Arch Capital.

OSCR's valuation aligns more closely with the tech-enabled peer ALHC than with traditional insurers, which suggests the market is pricing in a platform or data-distribution thesis rather than insurance underwriting quality. Its return on equity is weaker than Arch's and its net margin is volatile, so the multiple premium is not supported by current profitability on a peer-relative basis. The premium is justified only if the +Oscar platform and cost-to-serve advantages translate into sustained margin expansion.

Quarterly Combined Ratio Masks Reserve Effects

The combined ratio most commonly misapplied to OSCR is the single-quarter figure, which the 84.8% reading in 2026Q1 and 96.5% in 2026Q3 may overstate or understate underlying underwriting strength depending on reserve and risk adjustment timing.

Reading the combined ratio quarter by quarter treats medical cost estimates and risk adjustment true-ups as if they were recurring performance, when the swing from 111.9% to 84.8% within two quarters suggests much of the movement is timing rather than structural change. A trailing-twelve-month combined ratio, paired with reserve development disclosures where available, would give a steadier read on underwriting margin. Investors should monitor whether the 96.5% level holds once favorable prior-period development fades, since that is the figure most likely to be mistaken for durable profitability.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus & Technical Research Suite
Open OSCR Terminal

OSCR Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

OSCR — Frequently Asked Questions

Quick answers to the most common questions about buying OSCR stock.

What is Oscar Health, Inc.'s P/E ratio?

Oscar Health, Inc.'s current P/E ratio is 12.1x. The historical average is 140.4x.

What is Oscar Health, Inc.'s EV/EBITDA?

Oscar Health, Inc.'s current EV/EBITDA is 5.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 26.2x.

What is Oscar Health, Inc.'s ROE?

Oscar Health, Inc.'s return on equity (ROE) is -44.4%. The historical average is -31.6%.

Is OSCR stock overvalued?

Based on historical data, Oscar Health, Inc. is trading at a P/E of 12.1x. Compare with industry peers and growth rates for a complete picture.

What are Oscar Health, Inc.'s profit margins?

Oscar Health, Inc. has 14.4% gross margin and -3.4% operating margin.